Literature DB >> 20623824

A description of heterosexual couples' sexual adjustment to androgen deprivation therapy for prostate cancer.

Lauren M Walker1, John W Robinson.   

Abstract

OBJECTIVE: It is estimated that 600,000 men are currently living in North America with castrate levels of testosterone as a result of androgen deprivation therapy for prostate cancer. The goal of this study was to explore how patients and their partners adjust to changes associated with androgen deprivation therapy (ADT).
METHODS: Eighteen couples were interviewed regarding their adjustment to ADT side effects.
RESULTS: Three distinct patterns of adjustment were observed. One group of couples had assumed sex to be impossible after commencing ADT, and quickly accepted the loss of sex in exchange for a life extending treatment (four couples). Another group was found to be struggling to either maintain satisfying sex or adapt to the loss of their sexual relationship (five couples). The third group had struggled, but found that they were satisfied with their sexual outcome (nine couples). A subset of these couples successfully adjusted to changes in the man's sexual function and found satisfying ways to be sexually active (five couples).
CONCLUSIONS: The finding that some couples are able to enjoy satisfying sex, despite castrate levels of testosterone, raised questions about how patients are prepared to undergo ADT and how they are managed. It is possible that both the couples who gave up on sex because they believed that satisfying sex was impossible, and the couples who continued to struggle to adjust, may have faired better if they had known how other couples are able to maintain satisfying sex while the man is androgen-deprived.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20623824     DOI: 10.1002/pon.1794

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  8 in total

1.  Impact of androgen deprivation therapy on sexual function: a response.

Authors:  Erik Wibowo; Richard Wassersug; Karen Warkentin; Lauren Walker; John Robinson; Lori Brotto; Thomas Johnson
Journal:  Asian J Androl       Date:  2012-07-16       Impact factor: 3.285

Review 2.  Psychosocial perspectives on sexual recovery after prostate cancer treatment.

Authors:  Lauren M Walker; Richard J Wassersug; John W Robinson
Journal:  Nat Rev Urol       Date:  2015-03-10       Impact factor: 14.432

Review 3.  Prostate cancer and the impact on couples: a qualitative metasynthesis.

Authors:  Nicole Collaço; Carol Rivas; Lauren Matheson; Johana Nayoan; Richard Wagland; Obrey Alexis; Anna Gavin; Adam Glaser; Eila Watson
Journal:  Support Care Cancer       Date:  2018-03-06       Impact factor: 3.603

Review 4.  Sexual function in men undergoing androgen deprivation therapy.

Authors:  G Corona; S Filippi; P Comelio; N Bianchi; F Frizza; M Dicuio; G Rastrelli; S Concetti; A Sforza; L Vignozzi; M Maggi
Journal:  Int J Impot Res       Date:  2021-03-21       Impact factor: 2.896

5.  On the Relationship Between Erectile Function and Sexual Distress in Men with Prostate Cancer.

Authors:  Lauren M Walker; Pablo Santos-Iglesias
Journal:  Arch Sex Behav       Date:  2020-02-18

6.  Mood, sexuality, and relational intimacy after starting androgen deprivation therapy: implications for couples.

Authors:  Lauren M Walker; Pablo Santos-Iglesias; John Robinson
Journal:  Support Care Cancer       Date:  2018-05-18       Impact factor: 3.603

7.  The use of purposeful sampling in a qualitative evidence synthesis: A worked example on sexual adjustment to a cancer trajectory.

Authors:  Charlotte Benoot; Karin Hannes; Johan Bilsen
Journal:  BMC Med Res Methodol       Date:  2016-02-18       Impact factor: 4.615

8.  What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product.

Authors:  Irena Rot; Richard J Wassersug; Lauren M Walker
Journal:  Transl Androl Urol       Date:  2016-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.